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Abstract
Background: There is no consensus in the literature regarding the impact of false positive newborn screening
results on early health care utilization patterns. We evaluated the impact of false positive newborn screening results
for medium-chain acyl-CoA dehydrogenase deficiency (MCADD) in a cohort of Ontario infants.
Methods: The cohort included all children who received newborn screening in Ontario between April 1, 2006
and March 31, 2010. Newborn screening and diagnostic confirmation results were linked to province-wide health
care administrative datasets covering physician visits, emergency department visits, and inpatient hospitalizations,
to determine health service utilization from April 1, 2006 through March 31, 2012. Incidence rate ratios (IRRs) were
used to compare those with false positive results for MCADD to those with negative newborn screening results,
stratified by age at service use.
Results: We identified 43 infants with a false positive newborn screening result for MCADD during the study
period. These infants experienced significantly higher rates of physician visits (IRR: 1.42) and hospitalizations
(IRR: 2.32) in the first year of life relative to a screen negative cohort in adjusted analyses. Differences in health
services use were not observed after the first year of life.
Conclusions: The higher use of some health services among false positive infants during the first year of life
may be explained by a psychosocial impact of false positive results on parental perceptions of infant health,
and/or by differences in underlying health status. Understanding the impact of false positive newborn screening
results can help to inform newborn screening programs in designing support and education for families. This is
particularly important as additional disorders are added to expanded screening panels, yielding important clinical
benefits for affected children but also a higher frequency of false positive findings.
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Background
Population-based newborn screening programs aim to
pre-symptomatically identify newborns with treatable
rare conditions. Many such programs throughout the
world have expanded within the last decade [1], yield-
ing important clinical benefits to affected children [2].
Despite high specificities associated with newborn
screening tests, their positive predictive values are often
relatively low due to the low birth prevalence of the
screened diseases [3]. The expansion of newborn screen-
ing panels has consequently resulted in an overall in-
creased number of false positive results.
Published evidence is inconsistent regarding the po-
tential impact of false positive newborn screening results
on parental psychosocial experiences [4–9]. Regarding
health services use, some authors have observed higher
rates of emergency department visits or hospitalizations
among infants with false positive screening results, rela-
tive to screen-negative controls [7], yet others have
found no significant differences [3–5], or differences
only among preterm infants [10]. It is challenging to
ascribe any increases in health services use to the paren-
tal psychosocial impact of receiving a false positive re-
sult. Infants born preterm or with low birth weight are
more likely to receive positive newborn screening re-
sults in the absence of disease, due to their underlying
biology and the nature of the biochemical markers used
in the screening tests [10–12]. Abnormal values for
such markers may also reflect other factors related to
infant metabolism. Thus, increased health services use
might be attributable to health needs rather than the
screening result.
It has been hypothesized that false positive screening re-
sults for life-threatening illnesses such as medium-chain
acyl-CoA dehydrogenase deficiency (MCADD) might pro-
voke a stronger parental psychosocial response relative to
other diseases [10]. MCADD is an inherited metabolic dis-
ease included on newborn screening panels in many juris-
dictions [13, 14]. It affects the beta-oxidation pathway for
medium-chain fatty acids, critical in times of physio-
logical stress such as illness and fasting. Children diag-
nosed with MCADD have a hindered response to such
stress [14, 15] and are susceptible to potentially fatal
metabolic crises [16]. However, if early diagnosis is
established, prognosis is excellent [14, 15, 17, 18].
Newborn Screening Ontario coordinates newborn blood-
spot screening for approximately 140 000 babies born in
Ontario, Canada each year. MCADD was added to the
panel in April, 2006 [19]. All legal residents of Ontario are
eligible for universal health insurance through the Ontario
Health Insurance Plan (OHIP), encompassing a range
of medically necessary services. At the Institute for
Clinical Evaluative Sciences, encoded health care ad-
ministrative data can be securely linked to newborn
screening data with near complete population coverage
[20, 21]; these data include information on gestational
age and birth weight. This presents a unique opportun-
ity to investigate the impact of a false positive newborn
screening result while adjusting for important con-
founders. The objective of this study was to evaluate
whether children who received false positive newborn
screening results for MCADD experienced higher rates
of health services use in early life relative to a screen
negative cohort in Ontario.
Methods
This study was approved by the Ottawa Health Science
Network Research Ethics Board, Protocol # 20120229-01H.
Individual participant consent was not sought because the
study involved the secondary use of population-wide health
care administrative data.
Study population and data sources
Our source population included all children born in
Ontario who received newborn screening between April
1, 2006 and March 31, 2010. The false positive cohort
included children who received a positive newborn
screening result for MCADD but were ultimately deter-
mined to be unaffected. In Ontario, screening for
MCADD uses an algorithm involving C8 acylcarnitine
(octanoylcarnitine) as a primary analyte, with C6 (hexa-
noylcarnitine), C10 (decanoylcarnitine), C10:1 (decenoyl-
carnitine), C8/C10 ratio, and C8/C2 ratio as secondary
markers [19]. Infants who screen positive (potentially af-
fected) are referred to one of five regional Newborn
Screening Treatment Centres, which are based at pediatric
tertiary care centres in the province. The Treatment
Centre works with the infant’s primary health care pro-
vider to contact the parents and arrange for diagnostic
evaluation, and is also responsible for on-going follow-up
and management for affected children. The diagnostic
evaluation typically includes plasma acylcarnitine profil-
ing, urine organic acid analysis, and testing for mutations
in ACADM [19]. Neonates are classified by the Treatment
Centre and Newborn Screening Ontario medical staff re-
view results. Infants are classified as true positive if they
have a disease-associated genotype (e.g., homozygous for
the c.985A >G mutation), and/or have persistent abnor-
mal plasma acylcarnitines, and/or hexanoylglycine de-
tected on urine organic acids analysis. Infants with normal
metabolic profiles on diagnostic testing are defined as hav-
ing received false positive screening results.
A primary comparison cohort included all children
with negative newborn screening results for all disor-
ders during the same time period. A secondary com-
parison cohort included 10 controls with negative
screening results matched to each child with a false
positive result for MCADD, based on sex, calendar year
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of birth, urban-rural status of the child’s residence, and
an area-based indicator of socioeconomic status. The
purpose of the matched comparison cohort was to ad-
dress potential residual confounding by factors that
may be associated with access to health services. Indi-
viduals were excluded from the study if they were in-
eligible for health care coverage at the time of birth or
deceased within 24 h following birth (a bloodspot sam-
ple must be collected at > 24 h of age in Ontario to be
considered satisfactory).
Newborn screening diagnostic confirmation data were
securely linked to the provincial health care patient
registry at the Institute for Clinical Evaluative Sciences,
and then to administrative databases encompassing
health service visits from April 1, 2006 through March
31, 2012. Physician encounters were identified using
the OHIP Claims Database, which captures services
provided by Ontario physicians who bill OHIP on a
fee-for-service basis; and services provided by most
other Ontario physicians who work in capitation pay-
ment models [22]. Emergency department (ED) visit
data were retrieved from the Canadian Institute for Health
Information’s National Ambulatory Care Reporting Sys-
tem, covering nearly all ED visits in Ontario [20]. In-
patient hospitalization data were obtained from the
Canadian Institute for Health Information’s Discharge
Abstract Database, covering all acute inpatient facilities
in the province [21].
Potential confounding variables
Additional variables were ascertained from the hospi-
talization database at the time of birth (sex, birth
weight, gestational age, season of birth), and Census/
geographic data linked by the child’s postal code (so-
cioeconomic status, urban-rural status). We grouped
children into low (< 2500 g) and normal/high (≥ 2500 g)
birth weight categories. We dichotomized gestational age
to preterm (< 37 weeks) and term/post-term (≥ 37 weeks).
Season of birth was categorized as January–April, May–
August, or September–December.
A proxy measure of socioeconomic status was defined
as the neighborhood-level income quintile, based on
average household income data from the 2006 Canadian
Census, linked to a child’s residential postal code at birth
[23]. Neighborhoods were Census “dissemination areas”,
with populations of approximately 400–700 persons; in-
come quintiles were assigned across dissemination areas
within larger regions [24]. We merged the two lowest
and three highest quintiles to define lower and higher
socioeconomic status. Urban-rural status of the child’s
residence at birth was defined using the Rurality Index
for Ontario, based on population size and density and
on travel time to higher levels of hospital care [25]. We
defined a rural community using a score of ≥ 40, the cri-
terion used for rural physician eligibility in Ontario [26].
Utilization outcomes
We included each original health service encounter
within the study period (physician visits, ED visits, and
hospitalizations). If a child had multiple billed proce-
dures within a single physician visit, these were consid-
ered as one visit. However, if a child saw multiple
physicians on the same day, these were considered sep-
arate encounters. Each ED visit was a separate encounter
as was each inpatient hospitalization.
Statistical analysis
Study datasets were linked using unique encoded iden-
tifiers and analyzed at the Institute for Clinical Evalu-
ative Sciences; cell sizes < 6 were not reported due to
privacy policies. Counts and percentages were calcu-
lated and chi-square tests used to examine bivariate as-
sociations between sociodemographic characteristics
and cohort membership.
The number of physician visits, ED visits, and hospi-
talizations during the study period were summed for
each child. The length of follow-up for each individual
was the time elapsed between the date of birth and the
earliest of 3 possible end points: the date of OHIP eligi-
bility loss (mainly related to emigration from Ontario),
the date of death, or the last date of follow-up for the
study. Unadjusted visit rates and incidence rate ratios
(IRR) were calculated to compare the false positive and
screen negative cohorts.
Using the Vuong test as a criterion [27], we chose
negative binomial regression modeling to compute IRRs
for health services comparing the false positive with the
screen negative cohorts while adjusting for confounders.
Influential observations were identified [28, 29] and
truncated to the 99th percentile for each service type.
Models were stratified by age at the time of visit (< 1 year
of age and ≥ 1 year of age). As a sensitivity analysis to
address potential residual confounding by premature
birth, we re-ran final models restricted to children with
term births (≥ 37 weeks’ gestation). Finally, as a post-hoc
sensitivity analysis, we re-ran the final model for phys-
ician visits excluding the first month of life, when some
visits were likely related to resolving a positive screen as
a false positive. This 1-month period was based on the
clinical experience of metabolic physicians in Ontario.
Analyses were performed using SAS® version 9.3 (SAS
Institute, North Carolina, USA).
Results
Study population
Forty-three children had false positive newborn screening
results for MCADD during the study period. The primary
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comparison cohort consisted of 545,355 children. The
matched comparison cohort included 420 children identi-
fied as suitable matches for the false positive children.
Children with false positive results for MCADD were
more likely to be male, have a birth weight < 2500 g and
have a gestational age < 37 weeks relative to the primary
comparison group (Table 1). Follow-up time ranged from
less than one month to approximately 6 years of age
(mean and range: 49 months, < 1 to 67 months in the false
positive cohort; 48 months, < 1 to 77 months in the pri-
mary comparison group).
Health care visit rates
Children with false positive newborn screening results
for MCADD had 1939 recorded physician visits over the
follow-up period, with an average unadjusted visit rate
of 10.98 physician visits per child per year (Fig. 1). Chil-
dren in the primary and secondary comparison groups
had average rates of 8.44 and 9.00 physician visits per
child per year respectively. Those with false positive re-
sults for MCADD had a total of 105 ED visits over the
follow-up period with an average rate of 0.60 ED visits
per child per year; those in the comparison cohorts had
averages of 0.66 and 0.72 ED visits per child per year, re-
spectively. Finally, children with false positive newborn
screening results had a total of 27 inpatient hospitaliza-
tions over the follow-up period with an average rate of
0.15 hospitalizations per child per year. Those in the pri-
mary and secondary comparison groups had inpatient
hospitalization rates of 0.06 and 0.08 stays per child per
year, respectively.
Children in all 3 cohorts had the highest unadjusted
rates of physician use, ED visits, and hospitalization
rates during their first year of life (Fig. 1). In the first
year of life, children with false positive newborn screen-
ing results for MCADD had an average of 26.1 phys-
ician visits, 1.0 ED visits, and 0.5 hospital admissions
per child. These rates decreased to, on average, 6.3
physician visits, 0.5 ED visits, and 0.05 hospitalizations
per child per year in subsequent years of age. In the
first year of life, those in the primary comparison group
had on average 14.7 physician visits, 0.8 ED visits, and
0.1 hospitalizations per child; these rates similarly de-
creased in subsequent years to an average of 6.3 phys-
ician visits, 0.6 ED visits, and 0.04 hospitalizations per
child per year. Finally, in the first year of life, children
Table 1 Geographic and sociodemographic characteristics of the study population
Study Cohort
False Positive, n (%) Primary Comparison, n (%) Matched Comparison, n (%)
(n = 43) (n = 545 355) (n = 420)
Sexa,*
Male 28 (65.1) 279 638 (51.3) -
Female 15 (34.9) 265 717 (48.7) -
Month of Birth
January – April 19 (44.2) 177 918 (32.6) 142 (33.8)
May – August 8 (18.6) 192 896 (35.4) 134 (31.9)
Sept – December 16 (37.2) 174 541 (32.0) 144 (34.3)
Birth weight**
< 2500 g 6 (14.0) 33 027 (6.1) 28 (6.7)
≥ 2500 g 37 (86.0) 508 466 (93.2) 390 (92.9)
Gestational age***
< 37 weeks 11 (25.6) 42 235 (7.7) 34 (8.1)
≥ 37 weeks 32 (74.4) 489 232 (89.7) 373 (88.8)
Relative incomea
‘Lower’ 21 (48.8) 232 269 (42.6) -
‘Higher’ 21 (48.8) 310 003 (56.8) -
Urban–rural statusa,b
Rural < 6 (≤ 11.6) 34 111 (6.3) -
Urban 38–43 (≥ 88.4) 505 236 (92.6) -
* P < 0.10 for difference in proportion in the false positive cohort versus the comparison cohort
**P < 0.05 for difference in proportion in the false positive cohort versus the comparison cohort
***P < 0.01 for difference in proportion in the false positive cohort versus the comparison cohort
aCounts are not presented for secondary matched comparison group on matched variables
bResults are repressed for cell sizes < 6
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in the matched comparison group had on average 18.0
physician visits, 0.9 ED visits, and 0.2 hospitalizations
per child; these rates decreased in subsequent years to
an average of 6.6 physician visits, 0.7 ED visits, and
0.05 hospitalizations per child per year.
Incidence rate ratios for individual health care service types
In the first year of life, after adjusting for potential
confounding factors as previously described, children
with false positive results for MCADD had a statisti-
cally significant higher rate of physician visits (IRR:
1.42 [95 % CI: 1.21–1.67]) and inpatient hospitaliza-
tions (IRR: 2.32 [95 % CI: 1.22–4.34]) relative to the
primary comparison group; there was no significant
difference in the frequency of ED visits (IRR: 1.27
[95 % CI: 0.80–2.03]) (Table 2). There were no statisti-
cally significant differences for any of the three service
types in the false positive versus primary comparison
cohort among children older than 1 year of age. Re-
sults were similar for the false positive versus matched
comparison cohort, with the exception of ED visits
during the first year of life, where children with false
positive results had a relatively lower frequency of ED
visits (IRR: 0.81 [95 % CI: 0.52–1.27]) (Table 3); this
difference was not statistically significant.
When the age-stratified models were restricted to
children with term births (Table 4), the results were
similar to those reported for all births (Table 2). In the
first year of life, term children with false positive
screening results for MCADD had a statistically sig-
nificant higher rate of physician visits (IRR: 1.35 [95 %
CI: 1.13–1.63]) compared to term children with nega-
tive screening results. While there was no statistically
significant difference in hospitalization rates in the
two cohorts among term children less than 1 year of
age, the estimated IRR (IRR: 2.32 [95 % CI: 0.87–5.65)
Fig. 1 Unadjusted health service visit rates stratified by age at the time of visit (error bars show 95 % confidence intervals)
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was virtually identical to the IRR from the model for
all births (IRR: 2.32 [95 %: 1.22–4.34]). No statistically
significant differences were observed for health ser-
vices use among term children aged one year and
older. Finally, when we re-examined physician visits
over the first year of life in the entire cohort to ex-
clude the first month of life, children with false posi-
tive results still experienced higher rates of physician
care relative to those in the primary comparison group
(IRR: 1.31 [95%CI: 1.11–1.57]).
Table 2 Stratified adjusted models (< 1 year old and ≥ 1 year old) showing incidence rate ratios for the three service types,
comparing the false positive cohort with the primary (unmatched) comparison cohort
Adjusted incidence rate ratio (95 % CI)
< 1 year of age ≥ 1 year of age
Physician visits ED visits Hospitalizations Physician visits ED visits Hospitalizations
False Positive 1.42 (1.21–1.67) 1.27 (0.80–2.03) 2.32 (1.22–4.34) 0.96 (0.77–1.20) 0.82 (0.54–1.26) 0.68 (0.15–2.25)
Sex
Female 0.92 (0.91–0.92) 0.85 (0.85–0.86) 0.76 (0.75–0.77) 0.91 (0.91–0.92) 0.86 (0.85–0.87) 0.78 (0.77–0.80)
Male Reference Reference Reference Reference Reference Reference
Season of birth
Jan.–Apr. Reference Reference Reference Reference Reference Reference
May–Aug. 1.01 (1.00–1.01) 1.04 (1.03–1.05) 0.98 (0.96–1.00) 0.96 (0.95–0.96) 0.95 (0.95–0.96) 0.94 (0.92–0.97)
Sept.–Dec. 1.00 (1.00–1.01) 1.02 (1.00–1.03) 1.08 (1.06–1.11) 1.00 (0.99–1.00) 1.00 (0.99–1.00) 1.03 (1.00–1.05)
Birth weight
< 2500 g 1.75 (1.74–1.77) 1.04 (1.01–1.06) 2.14 (2.08–2.21) 1.13 (1.12–1.14) 1.03 (1.01–1.05) 1.59 (1.51–1.66)
≥ 2500 g Reference Reference Reference Reference Reference Reference
Gestational age
< 37 weeks 1.57 (1.56–1.58) 1.23 (1.21–1.26) 2.65 (2.57–2.73) 1.09 (1.09–1.10) 1.17 (1.15–1.19) 1.42 (1.36–1.48)
≥ 37 weeks Reference Reference Reference Reference Reference Reference
Socioeconomic status
‘Lower’ 1.00 (1.00–1.00) 1.23 (1.22–1.24) 1.09 (1.07–1.11) 0.96 (0.96–0.97) 1.12 (1.11–1.13) 1.10 (1.08–1.13)
‘Higher’ Reference Reference Reference Reference Reference Reference
Urban-rural status
Rural 0.79 (0.78–0.79) 2.34 (2.30–2.37) 1.16 (1.13–1.20) 0.73 (0.72–0.73) 2.28 (2.25–2.31) 1.15 (1.11–1.20)
Urban Reference Reference Reference Reference Reference Reference
Table 3 Stratified adjusted models (< 1 year old and ≥ 1 year old) showing incidence rate ratios for the three service types
(matched comparison group)
Adjusted incidence rate ratio (95 % CI)
< 1 year of age ≥ 1 year of age
Physician visits ED visits Hospitalizations Physician visits ED visits Hospitalizations
False Positive 1.45 (1.23–1.72) 0.81 (0.52–1.27) 2.20 (1.45–3.22) 1.00 (0.80–1.26) 0.81 (0.53–1.27) 0.60 (0.22–1.28)
Season of birth
Jan.–Apr. Reference Reference Reference Reference Reference Reference
May–Aug. 1.03 (0.94–1.13) 1.07 (0.86–1.32) 0.73 (0.53–1.02) 0.97 (0.86–1.09) 1.07 (0.87–1.33) 1.67 (1.20–2.34)
Sept.–Dec. 1.04 (0.95–1.13) 1.13 (0.91–1.41) 1.03 (0.77–1.39) 1.04 (0.92–1.16) 1.11 (0.90–1.38) 1.29 (0.90–1.86)
Birth weight
< 2500 g 1.64 (1.38–1.96) 1.26 (0.85–1.90) 1.46 (0.96–2.21) 1.18 (0.95–1.49) 1.27 (0.86–1.91) 1.60 (1.00–2.52)
≥ 2500 g Reference Reference Reference Reference Reference Reference
Gestational age
< 37 weeks 1.72 (1.46–2.02) 1.12 (0.77–1.65) 3.07 (2.08–4.43) 1.21 (0.99–1.50) 1.13 (0.78–1.65) 2.18 (1.38–3.34)
≥ 37 weeks Reference Reference Reference Reference Reference Reference
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Discussion
In this population-based study, after adjustment for po-
tential confounders, children with false positive newborn
screening results for MCADD experienced a statistically
significant higher frequency of physician visits and hos-
pitalizations, but not ED visits, as compared to screen
negative comparison groups in the first year of life. Our
findings are consistent with a Beijing study that identi-
fied a higher rate of parent-reported hospitalizations in
the first 6 months of life among children with false posi-
tive versus negative newborn screening results for a
range of metabolic disorders [7]. However, an American
study, also focused on metabolic disorders, found no sta-
tistically significant differences in parent-reported health
care use among infants with false positive versus nega-
tive screening results [3–5]. The only previous study
relying on administrative records, rather than parent re-
ports, involved a US Medicaid population and focused
on false positive results for metabolic, endocrine, or
hematologic disorders [10]. In that study the authors
identified no difference in health care use among chil-
dren with false positive versus negative screening re-
sults, with the exception of preterm infants, among
whom false positive results were associated with a
higher rate of acute outpatient visits [10]. However, the
authors hypothesized that the parental psychosocial re-
sponse may differ for different screened diseases [10].
To our knowledge, ours is the first disease-specific study
to compare health services use in these populations.
While the psychosocial consequences of a false posi-
tive newborn screening test are short-term for the
majority of parents, studies suggest that a small propor-
tion continue to experience anxiety following diagnostic
testing [30, 31]. Such anxiety, or misunderstanding of
the diagnostic result, could alter parental perceptions of
a child’s vulnerability to illness, similar to the well-
documented phenomenon of the “vulnerable child syn-
drome” [32]. As a result, such families may seek health
care at an increased frequency for their child. This is
one potential explanation for our findings with respect
to physician visits under 1 year of age. However, it is un-
likely to explain the increased hospitalizations under one
year of age in the false positive versus comparison group,
particularly in the absence of a similar increase in ED
visits. Given the rarity of MCADD and likely lack of ex-
perience with the disorder for most physicians, physician
perceptions may also have played a role. For example,
this may have resulted in a greater likelihood of hospital
admission among infants with false positive results pre-
senting to an ED, particularly if accompanied by parents
experiencing anxiety or confusion about the nature of
the result.
Another potential explanation for our findings that we
considered is that the increase in physician visits during
Table 4 Stratified adjusted models (< 1 year old and ≥ 1 year old) showing incidence rate ratios for the three service types for term
infants only, false positive cohort versus primary (unmatched) comparison cohort
Adjusted incidence rate ratio (95 % CI)
< 1 year of age ≥ 1 year of age
Physician visits ED visits Hospitalizations Physician visits ED visits Hospitalizations
False Positive 1.35 (1.13–1.63) 1.46 (0.87–2.51) 2.32 (0.87–5.65) 0.92 (0.72–1.19) 0.97 (0.60–1.55) 0.65 (0.10–2.60)
Sex
Female 0.92 (0.91–0.92) 0.86 (0.85–0.87) 0.75 (0.74–0.77) 0.86 (0.86–0.87) 0.86 (0.85–0.87) 0.78 (0.76–0.80)
Male Reference Reference Reference Reference Reference Reference
Season of birth
Jan.–Apr. Reference Reference Reference Reference Reference Reference
May–Aug. 1.01 (1.00–1.01) 1.04 (1.03–1.05) 0.98 (0.96–1.01) 0.96 (0.95–0.96) 0.95 (0.95–0.96) 0.94 (0.91–0.96)
Sept.–Dec. 1.00 (1.00–1.00) 1.02 (1.01–1.03) 1.09 (1.07–1.12) 1.00 (0.99–1.00) 1.00 (0.99–1.01) 1.02 (0.99–1.05)
Birth weight
< 2500 g 1.39 (1.38–1.41) 1.08 (1.04–1.11) 1.88 (1.78–1.99) 1.12 (1.10–1.13) 1.02 (1.00–1.05) 1.60 (1.50–1.71)
≥ 2500 g Reference Reference Reference Reference Reference Reference
Socioeconomic status
‘Lower’ 1.00 (1.00–1.00) 1.22 (1.21–1.24) 1.10 (1.07–1.12) 0.97 (0.96–0.97) 1.12 (1.11–1.13) 1.10 (1.08–1.13)
‘Higher’ Reference Reference Reference Reference Reference Reference
Urban-rural status
Rural 0.78 (0.78–0.79) 2.37 (2.33–2.41) 1.21 (1.16–1.25) 0.73 (0.72–0.73) 2.30 (2.27–2.33) 1.16 (1.11–1.21)
Urban Reference Reference Reference Reference Reference Reference
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the first year of life might reflect supplementary health
service visits related to confirmatory diagnostic testing
for the positive newborn screening result. However,
after excluding visits during the first month of life,
when the vast majority of diagnostic care would occur
for children with false positive results in Ontario, that
cohort still experienced a higher rate of physician visits
in the entire first year of life relative to screen-negative
controls.
A further possible explanation for the higher rate of
the use of certain health services in the first year of life
in children with false positive results is a residual con-
founding effect of premature birth. We adjusted for
gestational age and birth weight in our multivariable
analyses, since children with false positive results for
MCADD are more likely to be of lower gestation and
birth weight [10-12]. However, due to our small sample
size, we dichotomized both birth weight and gestational
age rather than using smaller categories as has been
recommended [33, 34]. To investigate a role for re-
sidual confounding by gestational age, we restricted the
analysis to children with gestational age ≥ 37 weeks. In
that analysis, the results for physician visits were simi-
lar to those in the main analysis and the results for hos-
pitalizations yielded the same effect size; this suggests
that residual confounding by gestational age does not
explain our findings.
Finally, it is possible that physiological differences aside
from gestational age and birth weight may be associated
with the biochemical markers used in the screening test
and may influence health care use during the first year of
life. For example, we did not have information about
underlying illnesses aside from those that are part of the
newborn screening panel. This potential explanation for
our findings is supported by a study that identified a
higher prevalence of low birth weight and/or time spent
in a neonatal intensive care unit in infants with elevated
screening markers for MCADD [35]. A limitation of using
health care administrative datasets is the lack of both clin-
ical detail and family-reported information. As a result, we
were unable to directly investigate the role of clinical char-
acteristics such as underlying illness and, similarly, we
could not directly study parental or physician perceptions
of infants’ health. Further research is needed to further ex-
plore these potential explanations. Should such research
confirm a psychosocial effect leading to higher health ser-
vice use, our findings support the use of strategies shown
to mitigate parental anxiety in the face of false positive
findings, including effective education and provider com-
munication during confirmatory follow-up [30, 36].
Conclusions
Infants with false positive newborn screening results for
MCADD may experience higher health care use in the
first year of life as a result of parental and physician per-
ceptions of their health status or unmeasured confound-
ing. More research is needed to investigate competing
explanations and to directly study the psychosocial im-
pact of false positive findings. Understanding the impact
of false positive newborn screening results can help to
inform newborn screening programs, and health care
providers involved in such programs, in designing sup-
port and education to benefit families of children re-
ceiving positive results. Specifically, if some parents or
non-metabolic specialist health care providers have
misperceptions about the health of children with false
positive newborn screening results, there may be a need
for further parental and provider education about the
clinically benign status of such results; and for add-
itional counselling services for parents who remain
concerned. This is particularly important as additional
disorders are added to expanded screening panels, lead-
ing to important clinical benefits for children with rare
treatable disorders but also a higher frequency of false
positive findings.
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